NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Tralokinumab for treating moderate to severe atopic dermatitis

Draft scope

Draft remit/appraisal objective
To appraise the clinical and cost effectiveness of tralokinumab within its marketing authorisation for treating moderate to severe atopic dermatitis.

Background
Atopic dermatitis (also known as atopic eczema) is a long-term condition that affects the skin. It is characterised by a red blotchy rash, dry, itchy and inflamed skin. The skin can also ooze and weep. Constant scratching can cause the skin to split and bleed, which can cause skin infections. Severe eczema can be physically disabling or incapacitating and can cause anxiety or depression.

Estimates of the prevalence of atopic dermatitis vary. It is more common in childhood (affecting 1 in 5 children in the UK) and affects 1 in 12 adults in the UK.1 Of the people who need treatment for atopic dermatitis 7% will have moderate to severe disease and around a third of these people will need a systemic treatment rather than an ointment.2

Atopic dermatitis is usually managed in primary care. Treatment strategies include advice on the avoidance of factors that can provoke dermatitis, such as soap, and the use of emollients to moisturise and relieve symptoms. For flares, or dermatitis that does not respond to these measures, topical corticosteroids are normally prescribed once or twice daily in conjunction with continued use of emollients (TA81). Tacrolimus ointment (calcineurin inhibitor) is recommended when moderate to severe atopic dermatitis has not been adequately controlled by use of topical steroids at the maximum strength and potency or where there is a serious risk of important adverse effects from further topical corticosteroid use, particularly irreversible skin atrophy (TA82). Allitretinoin is recommended as a possible treatment for people with severe chronic hand dermatitis affecting their quality of life and not responding to potent topical corticosteroids (TA177).

People with moderate or severe dermatitis not responding to topical treatments may be referred to secondary care and treated with stronger oral medications such as oral steroids, systemic immunosuppressants (azathioprine, ciclosporin, mycophenolate mofetil, and methotrexate). In addition, phototherapy and photochemotherapy (psoralen–ultraviolet A; PUVA) can be used to manage chronic severe atopic dermatitis.3

Dupilimumab is recommended as an option for treating moderate to severe atopic dermatitis in adults whose disease has not responded to at least 1 other systemic therapy, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are contraindicated or not tolerated (TA534)

The technology
Tralokinumab (brand name unknown, Leo Pharma UK) is an anti-interleukin (IL)-13 human immunoglobulin- G4 monoclonal antibody. It blocks the binding to IL-13 to its receptors. It is administered by subcutaneous injection
Tralokinumab does not have a marketing authorisation for treating people with moderate to severe atopic dermatitis and who are candidates for systemic therapy. It has been studied in clinical trials:

- In combination with topical corticosteroids compared with placebo in adults with severe atopic dermatitis that is not adequately controlled with cyclosporin A or for whom oral cyclosporin A is contraindicated
- In combination with topical corticosteroids compared with placebo in adults with moderate to severe atopic dermatitis
- As a monotherapy compared with placebo in adults with moderate to severe atopic dermatitis that is not adequately controlled with topical medications or for whom topical treatments are not appropriate.

<table>
<thead>
<tr>
<th>Intervention(s)</th>
<th>Tralokinumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population(s)</td>
<td>Adults with moderate to severe atopic dermatitis and who are candidates for systemic therapy</td>
</tr>
</tbody>
</table>
| Comparators     | • Phototherapy including with ultraviolet (UVB) radiation or psoralen-ultraviolet A (PUVA)  
• Immunosuppressive therapies (azathioprine, cyclosporin, methotrexate and mycophenolate mofetil)  
• Oral corticosteroids  
• Alitretinoin (in people with atopic dermatitis affecting the hands)  
• Dupilumab  
• Best supportive care (combination of emollients, low to mid potency topical corticosteroids, and rescue therapy including higher potency topical or oral corticosteroids or topical calcineurin inhibitors) |
| Outcomes        | The outcome measures to be considered include:  
• measures of disease severity  
• measures of symptom control  
• disease free period/maintenance of remission  
• time to relapse/prevention of relapse  
• adverse effects of treatment  
• health-related quality of life. |
### Economic analysis

The reference case stipulates that the cost effectiveness of treatments should be expressed in terms of incremental cost per quality-adjusted life year.

The reference case stipulates that the time horizon for estimating clinical and cost effectiveness should be sufficiently long to reflect any differences in costs or outcomes between the technologies being compared.

Costs will be considered from an NHS and Personal Social Services perspective.

### Other considerations

If the evidence allows the following subgroups will be considered:

- people with atopic dermatitis affecting the hands
- people for whom therapies have been inadequately effective, not tolerated or contraindicated
- skin colour subgroups.

Guidance will only be issued in accordance with the marketing authorisation. Where the wording of the therapeutic indication does not include specific treatment combinations, guidance will be issued only in the context of the evidence that has underpinned the marketing authorisation granted by the regulator.

### Related NICE recommendations and NICE Pathways

#### Related Technology Appraisals:

- **Dupilumab for treating moderate to severe atopic dermatitis** (2018) NICE technology appraisal guidance 534
- **Alitretinoin for the treatment of severe chronic hand eczema** (2009) NICE technology appraisal guidance 177
- **Tacrolimus and pimecrolimus for atopic eczema** (2004) NICE technology appraisal guidance 82
- **Frequency of application of topical corticosteroids for atopic eczema** (2004) NICE technology appraisal guidance 81

#### Appraisals in development (including suspended appraisals)

- **Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older (ID1195)** NICE technology appraisal guidance. Publication expected June 2020.
- **Baricitinib for treating moderate to severe atopic dermatitis (ID1622)**, NICE technology appraisal guidance. Expected publication date to be confirmed.

#### Related Guidelines:

- **Atopic eczema in under 12s: diagnosis and management** (2007) NICE guideline CG57
### Appendix B

#### Related Intervventional Procedures:
- *Grenz rays therapy for inflammatory skin conditions* (2007)
  NICE interventional procedures guidance 236

#### Related NICE Pathways:
- *Eczema* (2018) NICE pathway

#### Related National Policy

### Questions for consultation

#### Treatment pathway
- Is tralokinumab likely to be used in combination with topical corticosteroids or as a monotherapy in clinical practice?
- For a person needing systemic therapy to treat their atopic dermatitis would tralokinumab be used as a first systemic treatment or after immunosuppressive therapies (such as ciclosporin, methotrexate, azathioprine)?
- Would tralokinumab be used after dupilumab and vice versa?
- Would a person who is a ‘candidate for systemic therapy’ already have had phototherapy?

#### Comparators
- Have all relevant comparators for tralokinumab been included in the scope?
- Which treatments are considered to be established clinical practice in the NHS for people with moderate to severe atopic dermatitis who are candidates for systemic therapy?
- How should best supportive care be defined?

#### Outcomes
- Are the outcomes listed appropriate?

#### Subgroups

Draft scope for the appraisal of tralokinumab for treating moderate to severe atopic dermatitis. Issue Date: July 2020
© National Institute for Health and Care Excellence 2020. All rights reserved.
• Are the subgroups suggested in ‘other considerations appropriate?  
• Are there any other subgroups of people in whom tralokinumab is expected to be more clinically effective and cost effective or other groups that should be examined separately?

Where do you consider tralokinumab will fit into the existing NICE pathway Ecze‌ma?  

NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. Please let us know if you think that the proposed remit and scope may need changing in order to meet these aims. In particular, please tell us if the proposed remit and scope:

• could exclude from full consideration any people protected by the equality legislation who fall within the patient population for which tralokinumab will be/is/are/will be licensed;

• could lead to recommendations that have a different impact on people protected by the equality legislation than on the wider population, e.g. by making it more difficult in practice for a specific group to access the technology;

• could have any adverse impact on people with a particular disability or disabilities.

Please tell us what evidence should be obtained to enable the Committee to identify and consider such impacts.

Do you consider tralokinumab to be innovative in its potential to make a significant and substantial impact on health-related benefits and how it might improve the way that current need is met (is this a ‘step-change’ in the management of the condition)?

Do you consider that the use of tralokinumab can result in any potential significant and substantial health-related benefits that are unlikely to be included in the QALY calculation?

Please identify the nature of the data which you understand to be available to enable the Appraisal Committee to take account of these benefits.

To help NICE prioritise topics for additional adoption support, do you consider that there will be any barriers to adoption of this technology into practice? If yes, please describe briefly.

NICE intends to appraise this technology through its Single Technology Appraisal (STA) Process. We welcome comments on the appropriateness of appraising this topic through this process. (Information on the Institute’s Technology Appraisal processes is available at http://www.nice.org.uk/article/pmg19/chapter/1-Introduction).

NICE has published an addendum to its guide to the methods of technology appraisal (available at https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/methods-guide-addendum-cost-comparison.pdf), which states the methods to be used where a cost comparison case is made.
Appendix B

• Would it be appropriate to use the cost comparison methodology for this topic?

• Is the new technology likely to be similar in its clinical efficacy and resource use to any of the comparators?

• Is the primary outcome that was measured in the trial or used to drive the model for the comparator(s) still clinically relevant?

• Is there any substantial new evidence for the comparator technology/ies that has not been considered? Are there any important ongoing trials reporting in the next year?

References
